Low-dose paclitaxel synergizes with oncolytic adenoviruses via mitotic slippage and apoptosis in ovarian cancer

Oncogene. 2010 Nov 11;29(45):6051-63. doi: 10.1038/onc.2010.335. Epub 2010 Aug 23.


The microtubule-stabilizing drug paclitaxel has activity in relapsed ovarian cancer. dl922-947, an oncolytic adenovirus with a 24-bp deletion in E1A CR2, replicates selectively within and lyses cells with a dysregulated Rb pathway and has efficacy in ovarian cancer. In the aggressive A2780CP xenograft, combination treatment with weekly dl922-947 and paclitaxel has significantly greater efficacy than either treatment alone and can produce complete tumor eradication in some animals. We investigated the mechanisms of paclitaxel's synergy with dl922-947 in ovarian cancer. The host-cell microtubule network is grossly rearranged and stabilized following adenovirus infection, but paclitaxel does not increase this significantly. Paclitaxel does not synergize by increasing infectivity, viral protein expression or virus release. However, destabilizing the microtubule network with nocodazole reduces viral exit, revealing a novel microtubule-dependent pathway for non-lytic adenoviral exit. dl922-947 can override multiple cell cycle checkpoints but induces cell death by a non-apoptotic mechanism. In combination, dl922-947 and low-dose paclitaxel induces aberrant, multipolar mitoses, mitotic slippage and multinucleation, triggering an apoptotic cell death.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adenoviridae*
  • Animals
  • Apoptosis
  • Cell Line, Tumor
  • Female
  • Humans
  • Mice
  • Mice, Inbred BALB C
  • Microtubules / physiology
  • Mitosis
  • Oncolytic Virotherapy*
  • Ovarian Neoplasms / therapy*
  • Paclitaxel / administration & dosage*
  • Paclitaxel / pharmacology
  • Tubulin Modulators / administration & dosage
  • Tubulin Modulators / pharmacology*
  • Virus Replication
  • Xenograft Model Antitumor Assays


  • Tubulin Modulators
  • Paclitaxel